 CHARLOTTESVILLE, Va., Sept. 09, 2021 GLOBE NEWSWIRE -- Diffusion Pharmaceuticals Inc. NASDAQ: DFFN Diffusion or the Company, an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022. 